GLORIA MAGUADOG: Open Payments
NPI 1316105232 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,638 in 224 payments from 19 companies in 2025. Trend: 2023 $4,085 · 2024 $5,018 · 2025 $4,638
Food & beverage: $4,417Education: $221
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 33 | $883 |
| Teva Pharmaceuticals USA, Inc. | 35 | $745 |
| Otsuka America Pharmaceutical, Inc. | 33 | $620 |
| E.R. Squibb & Sons, L.L.C. | 27 | $480 |
| Alkermes, Inc. | 23 | $464 |
| Vanda Pharmaceuticals Inc. | 16 | $340 |
| Janssen Pharmaceuticals, Inc | 18 | $299 |
| Lundbeck LLC | 8 | $174 |
| Supernus Pharmaceuticals, Inc. | 7 | $133 |
| Tris Pharma Inc | 4 | $93 |
Products named: INGREZZA, REXULTI, COBENFY, ARISTADA, FANAPT, UZEDY, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
